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Background: Fibulin-1 is one of a few extracellular matrix proteins present in blood in high concentrations. We
aimed to define the relationship between plasma fibulin-1 levels and risk markers of cardiovascular disease.
Methods: Plasma fibulin-1 was determined in subjects with chronic kidney disease (n = 32; median age 62.5,
inter-quartile range 51 – 73 years) and 60 age-matched control subjects. Among kidney disease patients serological
biomarkers related to cardiovascular disease (fibrinogen, interleukin 6, C-reactive protein) were measured. Arterial
applanation tonometry was used to determine central hemodynamic and arterial stiffness indices.
Results: We observed a positive correlation of fibulin-1 levels with age (r = 0.38; p = 0.033), glycated hemoglobin
(r = 0.80; p = 0.003), creatinine (r = 0.35; p = 0.045), and fibrinogen (r = 0.39; p = 0.027). Glomerular filtration rate and
fibulin-1 were inversely correlated (r = −0.57; p = 0.022). There was a positive correlation between fibulin-1 and
central pulse pressure (r = 0.44; p = 0.011) and central augmentation pressure (r = 0.55; p = 0.001). In a multivariable
regression model, diabetes, creatinine, fibrinogen and central augmentation pressure were independent predictors
of plasma fibulin-1.
Conclusion: Increased plasma fibulin-1 levels were associated with diabetes and impaired kidney function.
Furthermore, fibulin-1 levels were associated with hemodynamic cardiovascular risk markers. Fibulin-1 is a candidate
in the pathogenesis of cardiovascular disease observed in chronic kidney disease and diabetes.
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The extracellular matrix protein fibulin-1 is emerging as a
new factor in cardiovascular disease. The plasma concen-
tration of fibulin-1 is a predictor of all cause and cardio-
vascular mortality in patients with diabetes mellitus [1].
Fibulin-1 belongs to a family of extracellular matrix
(ECM) proteins with functional associations with elastic
fibers and basement membranes. Fibulin-1 interacts with
a number of ECM molecules, but whether it serves a
structural role has not yet been established [2]. Fibulin-1
is expressed in embryonic and adult vascular smooth
muscle cells (VSMC) [3,4]. In adult blood vessels fibulin-1* Correspondence: ascholze@health.sdu.dk
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reproduction in any medium, provided the oris deposited in the medial layers surrounding VSMCs and
in association with elastic laminae and in the adventitial
ECM [1,4].
Fibulin-1 mRNA expression is increased in a model of
cardiomyopathy [5], and fibulin-1 plasma levels posi-
tively correlate with plasma N-terminal pro-B-type natri-
uretic peptide, a cardiac marker of pressure or volume
overload [1,6].
Several studies link fibulin-1 to atherosclerosis and
thrombosis, including studies showing that it binds fibri-
nogen, mediates platelet adhesion, is a component of
newly formed fibrin-containing thrombi and that it
accumulates in human atherosclerotic lesions [7-10].
Based on these findings fibulin-1 may be involved in
the development or progression of cardiovascular disease.
We tested the hypothesis that plasma fibulin-1 levels arel Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Population characteristics of chronic kidney
disease study participants
Characteristics
Age, years 62.5 (51 – 73)
Sex, men, n (%) 25 (78)
Body mass index, kg/m2 24.8 (21.7 – 28.1)
Smoking, n (%) 18 (56)
Underlying kidney disease, n (%)
Diabetic nephropathy 2 (6)
Nephrosclerosis 9 (28)
Glomerulonephritis 4 (13)
Others 17 (53)
Disease prevalence, n (%)
Diabetes 11 (34)
Hypertension 25 (78)
Peripheral artery disease 2 (6)
Coronary artery disease 9 (28)
Stroke 5 (16)
eGFR, mL/min/1.73 m2, * 39.9 (23.3 – 58.3)
Kt/V† 1.1 (0.9 – 1.4)
Medication, n (%)
Phosphate binder 16 (50)
Erythropoietin analog 15 (47)
Platelet aggregation inhibitor 8 (25)
Diuretic 7 (22)
ACE inhibitor/AT receptor antagonist 14 (44)
Calcium antagonist 15 (47)
ß-Blocker 12 (38)
Values are medians (25% - 75% percentile) or numbers (percentages), n = 32.
Abbreviations: ACE angiotensin converting enzyme, AT angiotensin,
eGFR estimated glomerular filtration rate, Kt/V = dialysis dose.
* n = 16, eGFR determination only in patients without hemodialysis therapy.
† n = 8.
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with chronic kidney disease and diabetes mellitus.
Methods
Study subjects
Chronic kidney disease (CKD) patients were recruited
from the outpatient population of the Department
of Nephrology, Odense University Hospital, Odense,
Denmark. Written informed consent was obtained
from each patient. The protocol was in accordance
with the ethical standards of the Declaration of Helsinki
and was approved by the regional ethics committee
(reference number: S-20090061). Fifty-seven measure-
ments were performed in 32 patients; 16 patients with
CKD stage 1 – 5 without hemodialysis therapy and
16 patients with hemodialysis therapy. In 25 of the
study participants two measurements per patient were
performed with an interval of 2 month. Population
characteristics are described in Table 1.
CKD was defined by structural or functional abnor-
malities of the kidney with or without decreased glome-
rular filtration rate (GFR) or estimated glomerular
filtration rate (eGFR) less than 60 mL/min/1.73 m2 for
more than 3 months. Estimated GFR was calculated
according to the Modification of Diet in Renal Disease
formula [11].
Hemodialysis (HD) patients were routinely dialyzed
for 4 to 5 hours, three times weekly. Dialyses were per-
formed using standardized techniques with bicarbonate-
based dialysates and controlled ultrafiltration rate. In
HD patients, the dialysis dose was calculated as the
amount of plasma cleared of urea divided by the urea
distribution volume (Kt/V). Diabetes was defined using
criteria of the American Diabetes Association or by a
history of or current treatment for diabetes mellitus.
Control samples for fibulin-1 determination were
obtained from 60 age- and sex-matched subjects without
kidney disease and without diabetes from the DanRisk
study population for the sole purpose of fibulin-1 con-
centration comparison (age, median 60 years, range
60 to 61; sex, 46 men, 77%; BMI (body mass index),
median 27.1 kg/m2, range 24.7 to 30.7; smoking, 21 par-
ticipants, 35%). Control samples were analyzed in the
same time frame and with the same pre-analytical condi-
tions as the study samples. The DanRisk study popula-
tion has been described previously [12].
Clinical and Biochemical Assessment
Examinations and blood samplings were performed
between 7 and 10 am. Examinations and blood sampling
in HD patients were performed before HD sessions.
Analyses were performed at the laboratories of the par-
ticipating departments according to current laboratory
standards.Plasma samples were obtained from EDTA-anticoagulated
blood and stored at −80°C. An ELISA for the determination
of fibulin-1 concentration was performed as described by
our group previously [1]. Briefly, 96-well plates were coated
with rabbit anti human fibulin-1 IgG (Rb2954 IgG;
Argraves et al., Cell, 1989) and blocked with bovine serum
albumin [13]. Plasma samples were used at a 1:1000 dilu-
tion and, after binding to the immobilized antibodies, were
incubated with anti-human fibulin-1 IgG (mouse monoclo-
nal, 3A11; Array Genetics, Newtown, Connecticut, USA).
Europium-labeled rabbit anti-mouse IgG (AD0124, Perkin
Elmer, Skovlunde, Denmark) was used as secondary anti-
body quantified by time-resolved fluorescence on DELFIA
(Perkin Elmer). Final fibulin-1 concentrations were derived
from a standard curve. The inter-assay variation was ≤ 10%.
Plasma samples for C-reactive protein (CRP), fibrinogen,
and interleukin-6 (IL6) were stored at −80°C. Fibrinogen
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(Siemens Healthcare Diagnostics Inc., Marburg, Germany).
A commercial ELISA was used to measure concentrations
of IL6 (Quantikine HS, R&D Systems, Abingdon, UK). The
inter-assay coefficients of variation were: < 10% for fibrino-
gen, < 6% for CRP, < 7% for IL6.
Glycated hemoglobin (HbA1C) was determined using
high-performance liquid chromatography as fraction
of total hemoglobin A0. Analyses were performed on
a Tosoh G7 automatic analyzer (Medinor, Broendby,
Denmark).
Blood pressure (BP) was measured after at least
10 minutes of supine resting in a quiet room prior to
blood sampling. The measurements were performed with
an automated device (Omron M6, Omron HealthCare
Europe B.V., Hoofddorp, Netherlands).
For pulse wave analysis an applanation tonometer
(Millar, SPT-301B, Houston, Texas, USA) was applied
to the radial artery. The recorded radial pressure wave-
forms and a corresponding brachial BP can be used to
generate the ascending aortic pressure waveform. For
this purpose a validated transfer function is used by
the SphygmoCorW system (version 7.0, Atcor Medical,
Sydney, Australia) [14]. We analyzed systolic aortic BP
(SBPaortic), diastolic aortic BP (DBPaortic), and aortic
pulse pressure (PPaortic).
The effect of pulse wave reflection on the incident
central pulse wave was evaluated using central augmen-
tation pressure (CAP), which was determined from the
difference between the first and the second aortic sys-
tolic pressure wave peaks. Aortic augmentation index
(AIxaortic) was derived from CAP expressed as percen-
tage of the central pulse pressure. Since the AIx depends
on heart rate we also analyzed the AIx normalized to a
heart rate of 75 beats per minute (AIx@75aortic). Aortic
pulse wave velocity (PWVaortic) was assessed as a direct
measure of arterial stiffness and determined between a
carotid artery and femoral artery recording site [15]. The
distance between the two measurement sites was deter-
mined by the subtraction method, hence by subtracting
the distance between the sternal notch to the carotid
artery from the sternal notch to the femoral artery.
Patients rested for 10 minutes in a supine position
before the measurements.
Statistics
In those patients were the measurements were per-
formed twice the mean of the obtained values was used
for the analyses. Normal distribution of continuous vari-
ables was tested by D’Agostino & Pearson omnibus nor-
mality test. Fibrinogen, IL6, CRP, creatinine, and PWV
did not show a normal distribution. Non-parametric
tests were therefore applied where necessary. Continu-
ous data are reported as median (25% - 75% percentile).Categorical variables are reported as numbers and per-
centages. Non-parametric bivariate correlation analysis
(Spearman) was performed. Multiple linear regression
analysis with backward selection was used to judge vari-
ables of significance for the prediction of plasma fibulin-
1 concentration.
Analyses were performed with GraphPad prism soft-
ware (version 5.0, GraphPad Software, San Diego, CA,
USA) and SPSS software (release 17.0, SPSS Inc., Chicago,
IL, USA). All statistical tests were two-sided and p-values
less than 0.05 were considered to indicate statistical
significance.
Results
The fibulin-1 study group contained 32 patients: 3 patients
with CKD 2 (eGFR more than 60 ml/min/1.73 m2),
7 patients with CKD stage 3 (eGFR 30–59 ml/min/
1.73 m2), 5 patients with CKD stage 4 (eGFR 15–29 ml/
min/1.73 m2), 1 patient with CKD stage 5 without
hemodialysis therapy (eGFR less than 15 ml/min/
1.73 m2). The remaining 16 patients were on chronic
hemodialysis treatment; their median dialysis vintage
was 42 (13–89) months. The clinical and biochemical
variables are given in Table 2.
Figure 1 shows the distribution of plasma fibulin-1 con-
centrations in patients with chronic kidney disease in the
absence and presence of diabetes mellitus as compared to
age- and sex-matched control subjects without kidney
disease and without diabetes (age, median 60 years, range
60 to 61; sex, 46 men, 77%; BMI, median 27.1 kg/m2,
range 24.7 to 30.7; smoking, 21 participants, 35%). Com-
pared to control subjects, patients with chronic kidney
disease showed higher fibulin-1 levels (p < 0.001). Further-
more, we observed significantly increased fibulin-1 con-
centrations in patients with chronic kidney disease plus
diabetes mellitus (median, 78 μg/mL; 74 to 113 μg/mL)
compared to patients with chronic kidney disease without
diabetes mellitus (median, 69 μg/mL; 49 to 79 μg/mL;
p < 0.050).
No differences in plasma fibulin-1 concentrations were
observed between males and females (Mann–Whitney test;
p = 0.964) or smokers and non-smokers (Mann–Whitney
test; p = 0.444).
Next we analyzed bivariate correlations between plasma
fibulin-1 concentration and clinical and biochemical vari-
ables (Table 3). We observed a positive correlation of
fibulin-1 with age and HbA1C concentration. Fibulin-1
levels correlated with markers of kidney function and
uremia (P-creatinine, P-urea, and eGFR) with fibulin-1
levels increasing with deteriorating kidney function/
increasing uremia. In hemodialysis patients, fibulin-1
concentrations were not correlated with dialysis dose
(Kt/V, r = −0.43; p = 0.300) or dialysis vintage (r = 0.17;
p = 0.537).
Table 2 Biochemical, hemodynamic and vascular
variables of chronic kidney disease study participants
Variable
P-Fibulin-1, μg/mL 73.9 (54.9 – 85.3)
HbA1C
* , % 7.2 (5.6 – 8.2)
P-Fibrinogen, μmol/L 11.7 (10.0 – 13.4)
P-IL6, pg/mL 5.03 (3.50 – 8.36)
P-CRP, mg/L 4.30 (1.52 – 11.86)
S-Albumin, g/l 41 (39 – 44)
P-Creatinine, μmol/L 380 (171 – 701)
P-Urea, mmol/L 15.2 (11.7 – 19.4)
SBP brachial, mmHg 138 (130 – 152)
DBP brachial, mmHg 77 (70 – 86)
SBP aortic, mmHg 128 (115 – 140)
DBP aortic, mmHg 79 (71 – 87)
PPaortic, mmHg 49 (34 – 59)
Heart rate, beats/min 70 (63 – 82)
CAP, mmHg 13 (8 – 21)
AIxaortic, % 31 (23 – 35)
AIx @75aortic, % 26 (21 – 32)
PWVaortic, m/s 10.1 (7.9 – 13.3)
Values are medians (25% - 75% percentile), n = 32.
Abbreviations: HbA1C glycated hemoglobin, IL6 interleukin 6, CRP C-reactive
protein, SBP systolic blood pressure, DBP diastolic blood pressure, PP pulse
pressure, CAP central augmentation pressure, AIx augmentation index, AIx@75
augmentation index at a heart rate of 75 beats/min, PWV pulse wave velocity.
* n = 12.
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Figure 1 Distribution of plasma fibulin-1 concentrations in
relation to diabetes occurrence and kidney function. Distribution
of plasma fibulin-1 concentrations in age- and sex-matched control
subjects without chronic kidney disease and without diabetes
(Control, n = 60) and patients with chronic kidney disease (CKD)
with (+Diab, n = 11) or without diabetes mellitus (−Diab, n = 21).
The plasma fibulin-1 values of the groups showed a significantly
different distribution (Kruskal-Wallis test p < 0.001). The differences
obtained by Dunn’s multiple comparison test are indicated in the
figure. Scholze et al., Figure 1.
Table 3 Bivariate correlation analysis of plasma fibulin-1
in chronic kidney disease study participants in relation to
clinical and biochemical variables (n = 32)
Variable r p
Age 0.38 0.033
HbA1C* 0.80 0.003
P-Fibrinogen 0.39 0.027
P-IL6 0.25 0.174
P-CRP 0.24 0.195
S-Albumin −0.30 0.102
P-Creatinine 0.35 0.049
P-Urea 0.51 0.004
eGFR† −0.57 0.022
SBPaortic 0.19 0.302
DBPaortic −0.41 0.019
PPaortic 0.44 0.011
Heart rate −0.35 0.047
CAP 0.55 0.001
AIxaortic 0.47 0.007
AIx@75aortic 0.23 0.203
PWVaortic 0.26 0.166
Abbreviations: HbA1C glycated hemoglobin, IL6 interleukin 6, CRP C-reactive
protein, eGFR estimated glomerular filtration rate, SBP systolic blood pressure,
DBP diastolic blood pressure, PP pulse pressure, CAP central augmentation
pressure, AIx augmentation index, AIx@75 augmentation index at a heart rate
of 75 beats/min, PWV pulse wave velocity.
* n = 12,
† n = 16, eGFR determination only in patients without hemodialysis therapy.
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lation between plasma levels of fibrinogen, a marker of
coagulation and systemic inflammation, and plasma fibu-
lin-1, whereas CRP and IL6 levels were not significantly
associated.
We also evaluated the degree to which plasma fibulin-1
levels were associated with hemodynamic variables and
established markers of arterial stiffness. Several key vari-
ables of central hemodynamics showed significant associa-
tions with plasma fibulin-1 levels (Table 3). A positive
correlation was found with aortic pulse pressure (PPaortic)
and central augmentation pressure (CAP), while a negative
correlation existed with heart rate. Markers of arterial stiff-
ness were also investigated. No association was observed
between plasma fibulin-1 and central pulse wave velocity.
Since the extent of pulse wave augmentation is also heart
rate dependent we used aortic augmentation index and
heart rate normalized AIx (AIx @75aortic). We did not
observe a significant association of plasma fibulin-1 con-
centrations with AIx@75aortic.
Multivariable regression analysis was performed to assess
the independent contributions of different variables to
plasma fibulin-1 concentration. According to the results of
the bivariate correlation analysis age, presence of diabetes,
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coagulation was taken into account. To avoid multicolli-
nearity between the hemodynamic variables, CAP was
chosen for the analyses. The results are presented in
Table 4. The presence of diabetes, creatinine, CAP, and
plasma fibrinogen concentration together explained 59% of
the variability of plasma fibulin-1 concentration in patients
with CKD.
Discussion
In the present study we show a positive association bet-
ween plasma fibulin-1 concentration and several cardiovas-
cular risk markers in patients with CKD. Our findings are
in accordance with findings from earlier experimental and
clinical studies which suggested links between fibulin-1,
cardiovascular disease and diabetes [7,9,16,17].
In the present study, plasma fibulin-1 concentration was
found to increase with age in the study population. This
is in agreement with our data previously published [1].
A multivariable analysis of the current data showed that
the importance of age is not retained in the simultaneous
context of kidney function, presence of diabetes, CAP and
fibrinogen status.
Correlations were also observed between markers of de-
teriorating kidney function and increasing plasma fibulin-1
concentrations, with creatinine being an independent pre-
dictor of plasma fibulin-1 concentration. These findings are
in accordance with findings from a multiplex proteomic
study showing that plasma fibulin-1 could be a marker of
renal impairment [18].
We also found an independent association between
fibulin-1 and fibrinogen, a positive acute phase protein
whose blood levels are increased in CKD. Fibrin clot
characteristics in CKD differ from non-CKD patients in
close correlation to inflammatory level rather than to
the extent of uremia [19]. Not only has fibulin-1 been
shown to bind to fibrinogen and incorporate into fibrin
thrombi, but fibulin-1 also qualitatively influences the
polymerization of fibrin [7,9,10]. We regard these fin-
dings as important in the context of increased plasma
fibulin-1 concentrations that we report here.Table 4 Multivariable regression analysis on plasma
fibulin-1
Independent variable Adjusted r2 F β p
model 0.59 11.98 <0.001
Diabetes 0.40 0.005
Creatinine 0.43 0.002
CAP 0.25 0.073
Fibrinogenlog 0.32 0.011
Age, presence of diabetes, creatinine, central augmentation pressure, and
logarithmically transformed plasma fibrinogen concentration were used in a
stepwise backward selection process (n = 32).
Abbreviations: CAP central augmentation pressure.Our previous studies demonstrated elevated plasma
concentrations of fibulin-1 in diabetic patients [1]. We
confirmed these results and again saw a correlation bet-
ween higher plasma fibulin-1 concentrations and higher
HbA1C values. The presence of diabetes was an inde-
pendent predictor of elevated plasma fibulin-1 levels.
The mechanism underlying the increase of plasma
fibulin-1 is not known. In patients with diabetes we
showed that it exists also in those patients without
microalbuminuria hence without signs of initial kidney
damage [1]. It should be noted, that diabetes and CKD
share important features at the molecular level, e.g. an
increase in oxidative stress and advanced protein glyca-
tion [20,21]. One or several factors from this group
might be involved in the regulation of plasma fibulin-1
concentration. This should be the subject of future ex-
perimental work.
An important dimension of the present study was the
analysis of central hemodynamics and vascular stiffness in
relation to plasma fibulin-1 concentrations. We found a
correlation with aortic AIx and central augmentation
pressure (CAP). CAP was retained as independent var-
iable in the multivariable analysis. When we performed
analyses of arterial stiffness markers we did not find a
correlation of plasma fibulin-1 concentrations to aortic
PWV and heart rate normalized aortic AIx. Thus, plasma
fibulin-1 seems to be unrelated to arterial changes that
result in changes of aortic PWV. Also, increased arterial
stiffness that results in an increased heart rate normalized
aortic AIx [22] was unrelated to plasma fibulin-1. By
contrast, a relationship was found to exist between plasma
fibulin-1 and the actual central augmentation the left
ventricle faces in the late systole. The pressure effort of
the ventricle to overcome this augmented pressure was
termed “wasted” since it does not contribute to blood flow
production [23].
Several potential new biomarkers for cardiovascular
diseases in diabetes have appeared during recent years.
These biomarkers are associated with dysfunctions in
different disease pathways and consequently display
both, similarities and discrepancies in their clinical
appearance.
While it was shown that plasma fibulin-1 was able to
predict all-cause mortality in patients with diabetes [1]
the underlying mechanisms which regulate the protein
amount in certain disease entities are still uncertain. A
similar dilemma applies for another interesting protein
that has extensively been studied in cardiovascular
disease – osteoprotegerin. Plasma osteoprotegerin con-
centrations are positively correlated to the presence of
coronary, carotid and peripheral artery disease in dia-
betic patients [24,25]. Elevated plasma osteoprotegerin
concentrations also predicted all-cause mortality in
diabetes [26]. Several interesting mechanisms for the
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dity, like an increased expression of adhesion molecules
by endothelial cells or a regulative effect on vascular calci-
fication, were described (for review see [27]). Although
the function of fibulin-1 in the cardiovascular system is
not well defined it could be speculated that it is different
from osteoprotegerin; more related to changes in the
structure of the extracellular matrix. Such functional
differences between biomarkers are likely to give rise to a
different clinical meaning. Nevertheless, the proof of a
cause-effect relation between cardiovascular disease in
humans and osteoprotegerin or fibulin-1 is still lacking
and the role of both proteins for diagnosis or assessment
of progression of cardiovascular disease awaits further
study.
The exact role of fibulin-1 in cardiovascular disease
may be complex since it is associated with pathologies
in both, arterial and heart tissue. In diabetes an accumu-
lation of fibulin-1 in the arterial wall and in plasma has
been described. Plasma fibulin-1 correlated significantly
with left atrial volume index and plasma N-terminal
pro-B-type natriuretic peptide [1]. On the other hand, a
down-regulation of fibulin-1 has been described in atrial
fibrillation [28].
With respect to the above described results from our
study and from previously presented investigations we
find it reasonable to speculate that in clinical conditions
with increased plasma fibulin-1 such as diabetes or
chronic kidney disease plasma fibulin-1 may be involved
in disease pathways which contribute to thrombotic and
cardiovascular complications. Furthermore, plasma
fibulin-1 displays a potential as cardiovascular biomarker
which awaits further studies.
Conclusions
In summary, we demonstrate an increase in plasma
fibulin-1 concentration in association with diabetes and
impaired kidney function. A positive association exists
between plasma fibulin-1 and fibrinogen levels. Also, an
increase of central augmentation pressure and augmen-
tation index resulting in higher left ventricular systolic
loading is associated with higher fibulin-1 plasma con-
centrations. These associations of plasma fibulin-1 are
compatible with the idea that fibulin-1 may have a role
in the complex pathogenesis of cardiovascular disease.
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